5 completed, 4 unknown, 2 active not recruiting, 2 recruiting. 14 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 5, Unknown 4, Active not recruiting 2, Recruiting 2, Terminated 1 |
| Phase 1 | 5 | Unknown 3, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow GIST: new trials by email Literature Review of GIST trials Research Report on GIST
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) KQB198, Imatinib (Gleevec) - GIST - Gastrointestinal Stromal Tumor, GIST | Phase 2 | Recruiting | Kumquat Biosciences Inc. | 46 | 2026-06-23 | 2026-08-10 |
| Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients Lenvatinib Capsules - GIST | Phase 1 / Phase 2 | Recruiting | Asan Medical Center | 48 | 2025-10-29 | 2026-04-03 |
| SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Bezuclastinib in combination with sunitinib - Gastrointestinal Stromal Tumors, GIST | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 40 | 2024-08-01 | 2025-10-31 |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Inlexisertib, Ripretinib - GIST | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 94 | 2023-09-28 | 2026-10-20 |
| Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy Stereotactic radiotherapy - Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 33 | 2020-12-01 | 2022-12-07 |
| NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours Intraoperative near-infrared fluorescence imaging using indocyaninegreen - GIST | Phase 2 / Phase 3 | Unknown | Leiden University Medical Center | 10 | 2020-06-17 | 2021-02-18 |
| Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) Selinexor, Imatinib - Maximum Tolerated Dose, GIST | Phase 1 / Phase 2 | Unknown | Grupo Espanol de Investigacion en Sarcomas | 30 | 2019-08-16 | 2023-03-27 |
| Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Temozolomide - Gastrointestinal Stromal Tumors, Sdh | Phase 2 | Completed | Adam Burgoyne, MD, PhD | 23 | 2018-09-12 | 2026-07-28 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors Vandetanib - GIST | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2013-12-14 | 2020-03-30 |
| A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Ponatinib - GIST | Phase 2 | Completed | Ariad Pharmaceuticals | 45 | 2013-06-05 | 2018-05-18 |
| Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) Pazopanib, Best supportive care - GIST | Phase 2 | Completed | Centre Leon Berard | 81 | 2011-03-01 | 2016-02-25 |
| Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Nilotinib, Nilotinib with Imatinib - GIST, Metastatic Disease | Phase 2 | Terminated | Fox Chase Cancer Center | 5 | 2009-02-01 | 2017-03-15 |
| An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) BIIB021 - GIST | Phase 2 | Completed | Biogen | 20 | 2008-02-01 | 2015-10-02 |
Gastrointestinal Stromal Tumors (5) · Neoplasm Metastasis (3) · Sarcoma (3) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Digestive System Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Duodenal Neoplasms (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Gastrointestinal Neoplasms (1) · Hematoma, Subdural (1) · Mesothelioma, Malignant (1)
Neoplasms (8) · Digestive System Diseases (7) · Gastrointestinal Diseases (7) · Neoplasms by Histologic Type (7) · Neoplasms, Connective and Soft Tissue (7) · Digestive System Neoplasms (6) · Gastrointestinal Neoplasms (6) · Neoplasms, Connective Tissue (5) · Pathological Conditions, Signs and Symptoms (5) · Neoplasms by Site (4) · Pathologic Processes (4) · Neoplastic Processes (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Pathological Conditions, Anatomical (2)
Imatinib Mesylate (3) · 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine (1) · Clinical Trials, Phase II as Topic (1) · Drug Combinations (1) · Pharmaceutical Preparations (1) · Radiosurgery (1) · Sunitinib (1) · Temozolomide (1) · lenvatinib (1) · nilotinib (1) · pazopanib (1) · ponatinib (1) · regorafenib (1) · ripretinib (1) · selinexor (1)
Adam Burgoyne, MD, PhD (1) · Ariad Pharmaceuticals (1) · Asan Medical Center (1) · Biogen (1) · Centre Leon Berard (1) · Deciphera Pharmaceuticals, LLC (1) · Erasmus Medical Center (1) · Fox Chase Cancer Center (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Institut Bergonié (1) · Kumquat Biosciences Inc. (1) · Leiden University Medical Center (1) · National Cancer Institute (NCI) (1) · Sarcoma Alliance for Research through Collaboration (1)
United States (8) · France (3) · Netherlands (3) · Spain (2) · Denmark (1) · Germany (1) · Italy (1) · Portugal (1) · South Korea (1) · Switzerland (1)
Adam Burgoyne, MD, PhD (1) · Andrew Wagner, MD, PhD (1) · Brigitte C Widemann, M.D. (1) · Candace Haddox, MD (1) · Cesar Serrano, MD (1) · Jason Sicklick, MD (1) · Margaret von Mehren, MD (1)
PMID 27068858, PMID 34965951, PMID 34998048, PMID 39317507, PMID 40204996, PMID 40579407
2016 (1), 2017 (1)